Published in
American Society of Hematology, Blood, 18(128), p. 2241-2252
DOI: 10.1182/blood-2016-01-695395
Links
Tools
Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma.
Journal article published in 2016 by
Alejandra Gutierrez-Gonzalez,
Mónica Martinez-Moreno,
Noemí Arellano-Sanchez,
Rafael Samaniego 
,
Antonio Valeri,
Laura Salinas-Munoz,
Miguel Relloso,
Joaquín Martinez-Lopez,
Ángel L. Corbí,
Joaquín Teixido,
A. L. Corbi,
Ángeles García-Pardo,
Andrés Hidalgo ,
Paloma Sanchez-Mateos,
A. Garcia-Pardo
,
Antonio Valeri,
Laura Salinas-Munoz,
Miguel Relloso,
Joaquín Martinez-Lopez,
Ángel L. Corbí,
Joaquín Teixido,
A. L. Corbi,
Ángeles García-Pardo,
Andrés Hidalgo ,
Paloma Sanchez-Mateos,
A. Garcia-Pardo
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points We report strategies to reprogram macrophages as a novel approach to treat MM mouse models using pro-M1 and blocking M2 signals. MIF is upregulated in the bone marrow microenvironment of MM patients and plays an autocrine role in protumoral MØ polarization.